Tag: Intellia Therapeutics

Shares of gene-editing specialist Intellia Therapeutics have experienced significant momentum, driven by a major late-stage clinical development achievement. Investor enthusiasm ...

The biotechnology sector is witnessing remarkable momentum in Intellia Therapeutics, as the gene editing specialist makes significant strides with its ...

After a challenging period that saw its valuation cut in half, gene-editing specialist Intellia Therapeutics appears to be building a ...